Algernon NeuroScience (AGN Neuro) is a wholly owned private subsidiary of Algernon Pharmaceuticals (Algernon Pharma), and has been established to advance Algernon Pharma’s psychedelic DMT program for stroke and traumatic brain injury (TBI).


AGN Neuro has filed a Form 1-A offering statement with the U.S. Securities and Exchange Commission (the “SEC”), seeking qualification to raise up to USD $10M for AGN Neuro by offering up to 37.5% of its common shares, (including the maximum amount of bonus shares) with majority ownership residing with AGN Pharma, under a Tier II Regulation A+ offering (Reg A+). The capital raised will be used for research, development, and program management costs related to the completion of a Phase 1 and Phase 2a DMT stroke study.